drugset / Trial / NCT01420211

Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®

NCT01420211

Phase 1/2 Completed 45 enrolled University Medicine Greifswald
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The objective of the study is to assess the hepatic uptake of Primovist® after intravenous administration of 25 µmol/kg body weight in 56 healthy volunteers and in 60 patients with a liver disease in dependence on the OATP1B1- and OATP1B3-genotype.

Timeline

Start
2006-10
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadoxetate Disodium Diagnostic / imaging agent 25 unknown Intravenous

Indications